Regression analysis of survival outcomes in patients with or without complex karyotype
| . | . | . | Univariate analysis . | . | . | Multivariate analysis . | . |
|---|---|---|---|---|---|---|---|
| Variable . | n . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| OS | |||||||
| Complex karyotype | |||||||
| Without | 114 | 1 | .089 | — | — | ||
| With | 186 | 1.29 | 0.9626-1.718 | — | — | ||
| Age | |||||||
| ≥55 y | 162 | 1 | .226 | 1 | .025 | ||
| <55 y | 138 | 0.84 | 0.639-1.112 | 0.65 | 0.441-0.948 | ||
| Sex | |||||||
| Female | 130 | 1 | .98 | — | — | ||
| Male | 170 | 1 | 0.760-1.325 | — | — | ||
| Disease type | |||||||
| Acute | 183 | 1 | .017 | 1 | .004 | ||
| Nonacute | 117 | 1.4 | 1.062-1.853 | 1.57 | 1.158-2.119 | ||
| Conditioning regimen | |||||||
| MAC | 118 | 1 | .359 | 1 | .049 | ||
| RIC | 182 | 0.88 | 0.663-1.16 | .681 | 0.464-0.999 | ||
| Disease status at HSCT | |||||||
| CR | 110 | 1 | <.001 | 1 | <.001 | ||
| Non-CR | 190 | 1.82 | 1.347-2.452 | 1.93 | 1.405-2.662 | ||
| sIL2R level at diagnosis | |||||||
| sIL2R ≥20 000 | 144 | 1 | .963 | — | — | ||
| sIL2R <20 000 | 121 | 0.99 | 0.740-1.333 | — | — | ||
| ATL-related death | |||||||
| Complex karyotype | |||||||
| Without | 114 | 1 | .004 | 1 | <.001 | ||
| With | 186 | 1.93 | 1.237-3.017 | 2.38 | 1.440-3.915 | ||
| Age | |||||||
| ≥55 y | 162 | 1 | .13 | — | — | ||
| <55 y | 138 | 0.74 | 0.494-1.095 | — | — | ||
| Sex | |||||||
| Female | 130 | 1 | .38 | — | — | ||
| Male | 170 | 1.2 | 0.803-1.778 | — | — | ||
| Disease type | |||||||
| Acute | 183 | 1 | .64 | — | — | ||
| Nonacute | 117 | 0.91 | 0.606-1.363 | — | — | ||
| Conditioning regimen | |||||||
| MAC | 118 | 1 | .12 | — | — | ||
| RIC | 182 | 1.39 | 0.92-2.11 | — | — | ||
| Disease status at HSCT | |||||||
| CR | 110 | 1 | <.001 | 1 | <.001 | ||
| Non-CR | 190 | 2.35 | 1.499-3.678 | 2.52 | 1.589-3.997 | ||
| sIL2R level at diagnosis | |||||||
| sIL2R ≥20 000 | 144 | 1 | .22 | — | — | ||
| sIL2R <20 000 | 121 | 1.29 | 0.858-1.952 | — | — | ||
| TRM | |||||||
| Complex karyotype | |||||||
| Without | 114 | 1 | .22 | — | — | ||
| With | 186 | 0.78 | 0.531-1.154 | — | — | ||
| Age | |||||||
| ≥55 y | 162 | 1 | .78 | — | — | ||
| <55 y | 138 | 1.06 | .719-1.553 | — | — | ||
| Sex | |||||||
| Female | 130 | 1 | .3 | — | — | ||
| Male | 170 | .82 | .557-1.200 | — | — | ||
| Disease type | |||||||
| Acute | 183 | 1 | .006 | 1 | .003 | ||
| Nonacute | 117 | 1.72 | 1.169-2.522 | 1.88 | 1.241-2.843 | ||
| Conditioning regimen | |||||||
| MAC | 118 | 1 | .01 | 1 | .017 | ||
| RIC | 182 | 0.6 | 0.410-0.885 | 0.6 | 0.395-0.912 | ||
| Disease status at HSCT | |||||||
| CR | 110 | 1 | .89 | — | — | ||
| Non-CR | 190 | 0.97 | 0.657-1.438 | — | — | ||
| sIL2R level at diagnosis | |||||||
| sIL2R ≥20 000 | 144 | 1 | .31 | — | — | ||
| sIL2R <20 000 | 121 | 0.8 | 0.529-1.222 | — | — | ||
| . | . | . | Univariate analysis . | . | . | Multivariate analysis . | . |
|---|---|---|---|---|---|---|---|
| Variable . | n . | HR . | 95% CI . | P . | HR . | 95% CI . | P . |
| OS | |||||||
| Complex karyotype | |||||||
| Without | 114 | 1 | .089 | — | — | ||
| With | 186 | 1.29 | 0.9626-1.718 | — | — | ||
| Age | |||||||
| ≥55 y | 162 | 1 | .226 | 1 | .025 | ||
| <55 y | 138 | 0.84 | 0.639-1.112 | 0.65 | 0.441-0.948 | ||
| Sex | |||||||
| Female | 130 | 1 | .98 | — | — | ||
| Male | 170 | 1 | 0.760-1.325 | — | — | ||
| Disease type | |||||||
| Acute | 183 | 1 | .017 | 1 | .004 | ||
| Nonacute | 117 | 1.4 | 1.062-1.853 | 1.57 | 1.158-2.119 | ||
| Conditioning regimen | |||||||
| MAC | 118 | 1 | .359 | 1 | .049 | ||
| RIC | 182 | 0.88 | 0.663-1.16 | .681 | 0.464-0.999 | ||
| Disease status at HSCT | |||||||
| CR | 110 | 1 | <.001 | 1 | <.001 | ||
| Non-CR | 190 | 1.82 | 1.347-2.452 | 1.93 | 1.405-2.662 | ||
| sIL2R level at diagnosis | |||||||
| sIL2R ≥20 000 | 144 | 1 | .963 | — | — | ||
| sIL2R <20 000 | 121 | 0.99 | 0.740-1.333 | — | — | ||
| ATL-related death | |||||||
| Complex karyotype | |||||||
| Without | 114 | 1 | .004 | 1 | <.001 | ||
| With | 186 | 1.93 | 1.237-3.017 | 2.38 | 1.440-3.915 | ||
| Age | |||||||
| ≥55 y | 162 | 1 | .13 | — | — | ||
| <55 y | 138 | 0.74 | 0.494-1.095 | — | — | ||
| Sex | |||||||
| Female | 130 | 1 | .38 | — | — | ||
| Male | 170 | 1.2 | 0.803-1.778 | — | — | ||
| Disease type | |||||||
| Acute | 183 | 1 | .64 | — | — | ||
| Nonacute | 117 | 0.91 | 0.606-1.363 | — | — | ||
| Conditioning regimen | |||||||
| MAC | 118 | 1 | .12 | — | — | ||
| RIC | 182 | 1.39 | 0.92-2.11 | — | — | ||
| Disease status at HSCT | |||||||
| CR | 110 | 1 | <.001 | 1 | <.001 | ||
| Non-CR | 190 | 2.35 | 1.499-3.678 | 2.52 | 1.589-3.997 | ||
| sIL2R level at diagnosis | |||||||
| sIL2R ≥20 000 | 144 | 1 | .22 | — | — | ||
| sIL2R <20 000 | 121 | 1.29 | 0.858-1.952 | — | — | ||
| TRM | |||||||
| Complex karyotype | |||||||
| Without | 114 | 1 | .22 | — | — | ||
| With | 186 | 0.78 | 0.531-1.154 | — | — | ||
| Age | |||||||
| ≥55 y | 162 | 1 | .78 | — | — | ||
| <55 y | 138 | 1.06 | .719-1.553 | — | — | ||
| Sex | |||||||
| Female | 130 | 1 | .3 | — | — | ||
| Male | 170 | .82 | .557-1.200 | — | — | ||
| Disease type | |||||||
| Acute | 183 | 1 | .006 | 1 | .003 | ||
| Nonacute | 117 | 1.72 | 1.169-2.522 | 1.88 | 1.241-2.843 | ||
| Conditioning regimen | |||||||
| MAC | 118 | 1 | .01 | 1 | .017 | ||
| RIC | 182 | 0.6 | 0.410-0.885 | 0.6 | 0.395-0.912 | ||
| Disease status at HSCT | |||||||
| CR | 110 | 1 | .89 | — | — | ||
| Non-CR | 190 | 0.97 | 0.657-1.438 | — | — | ||
| sIL2R level at diagnosis | |||||||
| sIL2R ≥20 000 | 144 | 1 | .31 | — | — | ||
| sIL2R <20 000 | 121 | 0.8 | 0.529-1.222 | — | — | ||
Significant P values are in bold.
CR, complete response.